These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7776684)

  • 1. Immunohistochemical detection of P53 protein is not associated with a poor prognosis in non-small-cell lung cancer.
    Passlick B; Izbicki JR; Häussinger K; Thetter O; Pantel K
    J Thorac Cardiovasc Surg; 1995 Jun; 109(6):1205-11. PubMed ID: 7776684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micrometastatic P53-positive cells in the lymph nodes of non-small-cell lung cancer: prognostic significance.
    Dobashi K; Sugio K; Osaki T; Oka T; Yasumoto K
    J Thorac Cardiovasc Surg; 1997 Sep; 114(3):339-46. PubMed ID: 9305185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
    Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas.
    Mørkve O; Halvorsen OJ; Skjaerven R; Stangeland L; Gulsvik A; Laerum OD
    Anticancer Res; 1993; 13(3):571-8. PubMed ID: 8391242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
    Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
    Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer.
    Bennett WP; el-Deiry WS; Rush WL; Guinee DG; Freedman AN; Caporaso NE; Welsh JA; Jones RT; Borkowski A; Travis WD; Fleming MV; Trastek V; Pairolero PC; Tazelaar HD; Midthun D; Jett JR; Liotta LA; Harris CC
    Clin Cancer Res; 1998 Jun; 4(6):1499-506. PubMed ID: 9626468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
    Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
    Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients.
    Harpole DH; Marks JR; Richards WG; Herndon JE; Sugarbaker DJ
    Clin Cancer Res; 1995 Jun; 1(6):659-64. PubMed ID: 9816029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sialomucin expression is associated with erbB-2 oncoprotein overexpression, early recurrence, and cancer death in non-small-cell lung cancer.
    Yu CJ; Shun CT; Yang PC; Lee YC; Shew JY; Kuo SH; Luh KT
    Am J Respir Crit Care Med; 1997 Apr; 155(4):1419-27. PubMed ID: 9105088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer.
    Ebina M; Steinberg SM; Mulshine JL; Linnoila RI
    Cancer Res; 1994 May; 54(9):2496-503. PubMed ID: 7909277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer.
    Borner MM; Brousset P; Pfanner-Meyer B; Bacchi M; Vonlanthen S; Hotz MA; Altermatt HJ; Schlaifer D; Reed JC; Betticher DC
    Br J Cancer; 1999 Feb; 79(5-6):952-8. PubMed ID: 10070896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of altered pRb and p53 protein expression in surgically treated non-small cell lung cancer patients.
    Dworakowska D; Jassem E; Jassem J; Wiedorn KH; Boltze C; Karmoliński A; Dworakowski R; Skokowski J; Jaśkiewicz K; Bosse A; Czestochowska E
    Oncology; 2004; 67(1):60-6. PubMed ID: 15459497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871.
    Carbone DP; Mitsudomi T; Chiba I; Piantadosi S; Rusch V; Nowak JA; McIntire D; Slamon D; Gazdar A; Minna J
    Chest; 1994 Dec; 106(6 Suppl):377S-381S. PubMed ID: 7988268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do molecular markers predict survival in non-small-cell lung cancer?
    Greatens TM; Niehans GA; Rubins JB; Jessurun J; Kratzke RA; Maddaus MA; Niewoehner DE
    Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1093-7. PubMed ID: 9563724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2E1 polymorphism, cigarette smoking, p53 expression, and survival in non-small cell lung cancer: a long term follow-up study.
    Haque AK; Au W; Cajas-Salazar N; Khan S; Ginzel AW; Jones DV; Zwischenberger JB; Xie J
    Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):315-22. PubMed ID: 15536330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer.
    Kakolyris S; Giatromanolaki A; Koukourakis M; Powis G; Souglakos J; Sivridis E; Georgoulias V; Gatter KC; Harris AL
    Clin Cancer Res; 2001 Oct; 7(10):3087-91. PubMed ID: 11595699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer.
    Zhang Z; Ma J; Li N; Sun N; Wang C
    Ann Thorac Surg; 2006 Jul; 82(1):243-8. PubMed ID: 16798222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.